Stockreport

Chardan Capital upgrades Arbutus Biopharma, sees almost 40% upside; shares ahead 8% [Seeking Alpha]

Arbutus Biopharma Corporation  (ABUS) 
Last arbutus biopharma corporation earnings: 11/6 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.arbutusbio.com/node/5806
PDF Arbutus Biopharma ( ABUS ) moves up on double normal volume on the heels on an upgrade to Buy from Neutral by Chardan Capital with a $1 boost in the price target [Read more]